Loading…
← CockpitCompetitor Analysis › ALMR Alamar Biosciences, Inc.Open in the cockpit ↗

Alamar Biosciences, Inc.ALMRCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Makes an ultra-sensitive proteomics platform (NULISA) that detects trace protein biomarkers for research and diagnostics.

Momentum leader 84
Mkt cap
$2.12B
US dollars, full cap
Free float
52%
of shares outstanding
$/day
$22.2M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-27.3 pp
WACC 6.5%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$30.51
1D-0.4%
1W-3.5%
1M+8.3%
3M-11.9%
6M+51.3%
YTDn/a
1Yn/a
ATR %8.3%
52w lowhigh23.0% off high

What Alamar Biosciences does

Makes an ultra-sensitive proteomics platform (NULISA) that detects trace protein biomarkers for research and diagnostics.

Sells instruments and then earns repeatedly on the assay kits used on them, so reagent sales follow the number of samples customers run. Customers are mostly research labs, so research-grant funding affects demand.

Products and services

  • NULISA platform (protein detection assays)
  • Biomarker panels for research use

Customers

  • Academic research labs
  • Pharma/biotech R&D

Where it sits in the supply chain

  • Health Care
  • Life science tools
  • Proteomics biomarker detection

What could go right

  • Proteomics research market growth
  • Panel and menu expansion

What could go wrong

  • Competitive proteomics tools field
  • R&D budget cyclicality among customers

Moat: narrow (IP / patents, process know-how). Proprietary ultra-sensitive protein detection technology differentiated from standard immunoassays.

Headquarters: Fremont, California, US · Founded: 2018 · Employees: 222

Named competitors

Alamar Biosciences at a glance

Size Alamar Biosciences (ALMR) is a United States Health Care company (Biotechnology) with a market value of $2.12B, the 1737th largest of 3,085 United States companies the cockpit tracks. Shares closed at $30.51 on 18 Nov 2026.

Performance Over six months the shares gained 51.3%, against -10.8% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 20 in its peer set.

Growth Revenue grew 195.2% over the last twelve months (peer median +4.1%); the operating margin is -42.2% (peer median -19.9%).

Valuation It trades at 26.1× enterprise value to sales against a peer median of 9.8× (3rd most expensive of 15).

Capital Return on invested capital runs 27.3 points below its cost of capital (6.5% WACC).

Short interest Short interest is 3.2% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026ALMR 139Peer median 92
Six months, rebased to 100: Alamar Biosciences against the median of its 20 peers (local-currency closes).

Alamar Biosciences financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024
Revenuen/a$74.2M$25.1M
Revenue growth—+195%—
Gross profitn/a$41.7M$8.61M
EBITDAn/a-$27.5M-$46.4M
Net incomen/a-$29.8M-$47.1M
Free cash flown/a-$59.0M-$58.2M
Capital expendituren/a$6.38M$3.39M
Total debt$42.4M$276M$268M

Quarterly statements and history in the cockpit →

Alamar Biosciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%0%+50%300676PVLAZEALCLDXBEAMPHVS302440VIMIANRCUS300255MRVIREPLSEPNALMR6-month return →1-month return →
Up and to the right = strong over both horizons. Alamar Biosciences is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%+200%+300%0×5,000×10,000×300676ZEALCLDXBEAMAUPHRCUSBCRXSEPNALMRRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Alamar Biosciences is the large dot.

Alamar Biosciences competitors and peer comparison

Head to head with its named competitors (ALMR vs TMO vs LAB vs TECH)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Alamar Biosciences ALMR$2.12B+51%+195%-42%26.1×n/a
Thermo Fisher Scientific TMO$257B+53%+8%19%6.2×21.3%
Standard BioTools LABn/a-46%n/an/an/an/a
Bio-Techne TECH$11.4B+56%+1%21%9.2×31.6%
Nautilus Biotechnolgy NAUT$310M+2%n/a-15,106%588.9×n/a

How Alamar Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Alamar Biosciences against its 20 peers (data as of 18 Nov 2026)
MeasureALMRPeer medianRank in peer set
1-month return+8.3%-4.9%5th highest of 21
6-month return+51.3%-10.8%3rd highest of 20
Distance from 52-week high-23.0%-34.1%7th highest of 21
Revenue growth (TTM)+195.2%+4.1%3rd highest of 17
Operating margin-42.2%-19.9%6th lowest of 15
EV / Sales26.1×9.8×3rd most expensive of 15
ROIC minus cost of capital-27.3 pp-11.0 pp2nd lowest of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Alamar Biosciences ALMRUnited States$2.12B+51%+195%-42%26.1×n/an/a
BGI Genomics 300676.SZChina$2.13B-15%0%-14%3.2×n/an/a
Palvella Therapeutics PVLAUnited States$2.14B+27%-100%n/an/an/an/a
Zealand Pharma A/S ZEAL.CODenmark$2.16B-30%-50%46%0.4×n/an/a
Celldex Therapeutics CLDXUnited States$2.16B-11%-94%-211,685%9,677.0×n/an/a
Evopoint Biosciences 688837.SSChina$2.08Bn/an/an/a53.6×n/an/a
Beam Therapeutics BEAMUnited States$2.17B-22%+163%-268%9.4×n/an/a
Pharvaris PHVSUnited States$2.21B+7%n/an/an/an/an/a
Aurinia Pharmaceuticals AUPHUnited States$2.03B-5%+21%45%5.0×3.5%+41.4%
SKBS 302440.KSSouth Korea$2.25B-12%+11%-23%4.3×n/an/a
Vimian VIMIAN.STSweden$2.26B+51%+8%19%5.0×13.4%+44.5%
Lakefront Biotherapeutics LKFT.ASNetherlands$2.26B+31%+223%64%n/an/an/a
Immunome IMNMUnited States$1.98B-22%-100%n/an/an/an/a
Arcus Biosciences RCUSUnited States$2.27B-34%-58%-475%17.6×n/an/a
Hebei Changshan Biochemical Pharmaceutical 300255.SZChina$2.33B-59%0%-25%19.4×n/an/a
Trevi Therapeutics TRVIUnited States$1.93B-3%n/an/an/an/an/a
Maravai Lifesciences MRVIUnited States$1.92B+101%+11%-17%10.2×n/an/a
Sinocelltech 688520.SSChina$1.90B-35%-40%-75%13.6×n/an/a
BioCryst Pharmaceuticals BCRXUnited States$1.88B-16%+60%42%2.4×-11.0%+117.9%
Replimune REPLUnited States$1.88B+321%n/an/an/an/an/a
Septerna SEPNUnited States$1.88B+41%+337%-76%14.7×n/an/a

Questions

Who are Alamar Biosciences's main competitors?
Named competitors: Olink (Thermo Fisher) (TMO), Standard BioTools (LAB), Quanterix (private or unlisted), Seer (private or unlisted), Bio-Techne (TECH), Nautilus Biotechnology (NAUT). The cockpit's measured peer set (industry) also includes BGI Genomics (300676.SZ), Palvella Therapeutics (PVLA), Zealand Pharma A/S (ZEAL.CO), Celldex Therapeutics (CLDX), Evopoint Biosciences (688837.SS), Beam Therapeutics (BEAM).
Is Alamar Biosciences expensive compared with its peers?
On ev / sales it trades at 26.1× against a peer median of 9.8×, 3rd most expensive of 15 in its peer set.
How has Alamar Biosciences stock performed?
Over six months to 18 Nov 2026 the shares returned +51.3% against -10.8% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.